The vasodilatation that occurs in skeletal muscle during systemic hypoxia represents a balance between the vasoconstrictor effects of increased muscle sympathetic nerve activity (MSNA) and the dilator influences of local mediators and circulating adrenaline ([@b32]). Thus, in the rat, α-adrenoceptor blockade enhanced the decrease in muscle vascular resistance induced by systemic hypoxia and dilator responses in individual skeletal muscle arterioles, while converting arteriolar constrictor responses to dilator responses ([@b33]; [@b36]). Similarly, in human subjects vasodilatation evoked in forearm by systemic hypoxia was augmented by α-adrenoceptor blockade ([@b61]). Such observations raise the question of whether the vasoconstrictor influence of MSNA is blunted during systemic hypoxia, or there is summation of constrictor and dilator influences and the latter dominates.

There is some evidence that vasoconstriction evoked by increased MSNA is indeed blunted by systemic hypoxia. Reflex vasoconstriction evoked in forearm by lower body negative pressure (LBNP) was reduced by mild and moderate systemic hypoxia (breathing 12 and 10% O~2~, respectively; [@b18]). Moreover, the increases in MSNA evoked by LBNP were preserved during mild and moderate hypoxia, but the forearm vasoconstrictor responses were reduced ([@b50]). However, reflex vasoconstriction evoked by LBNP in muscle microcirculation, as assessed by near infra-red spectroscopy, was well maintained during moderate hypoxia ([@b17]). Further, forearm vasoconstriction evoked by tyramine, which releases noradrenaline from sympathetic fibres, was preserved during mild and moderate hypoxia ([@b8]).

Such disparities may be attributable to differences in the levels of hypoxia and methods used to activate the sympathetic nerves. In anaesthetized rats, we stimulated the sympathetic chain with three different patterns that delivered the same number of impulses over 1 min (see [@b6]): continuous stimulation at 2 Hz to represent a low, resting level of MSNA and bursts of impulses at 20 or 40 Hz to represent the high frequency bursts that occur when MSNA is raised, for example by systemic hypoxia ([@b30]; [@b24]; [@b19]). The increases in femoral vascular resistance (FVR) evoked by bursts at 20 and 40 Hz were not affected by mild or moderate hypoxia, but were considerably blunted by severe hypoxia (8% O~2~): that evoked by continuous stimulation at 2 Hz was blunted by moderate, as well as severe, hypoxia ([@b6]).

These blunting effects were not altered by adenosine receptor blockade, or inhibition of cyclooxygenase activity ([@b6]; [@b60]), even though the muscle vasodilatation of systemic hypoxia is largely mediated by adenosine with prostacyclin acting as an intermediate ([@b4]; [@b49]). Further, they could not be ascribed to NO generated by endothelial, or neuronal NOS ([@b5]), even though the hypoxia-induced vasodilatation is largely NO dependent ([@b53]).

In view of these findings, the question arises as to whether systemic hypoxia influences the action of the sympathetic cotransmitters. *In vitro* studies indicate that ATP makes the major contribution to vasoconstriction evoked in arteries by single impulses or short trains at low frequency, while noradrenaline becomes important when the impulse train is longer or the frequency increases ([@b26]; [@b52]). On the other hand, *in vivo* studies on rat hindlimb suggest that ATP and noradrenaline are mutually facilitatory in producing vasoconstriction evoked by sympathetic stimulation with low and high frequencies ([@b23]). Further, *in vivo* studies on skeletal muscle indicate that sympathetic stimulation at constant high frequency, or with irregular activity containing high frequency bursts releases neuropeptide Y (NPY), while in various arterial preparations, high frequency patterns evoke NPY-mediated contstiction ([@b45]; [@b39]).

Considering these transmitters, the fact that A~1~ or A~2A~ adenosine receptor blockade had no effect on hypoxia-induced blunting of sympathetically evoked vasoconstriction (see above, [@b6]) indicates that it is not caused by pre- or postsynaptic actions of adenosine formed from sympathetically released ATP ([@b48]). Hypoxia may affect the postsynaptic actions of ATP, but this is difficult to test *in vivo* in the absence of selective P2X receptor antagonists. Severe systemic hypoxia inhibits vasoconstriction evoked by noradrenaline infusion in rats ([@b6]) and humans ([@b18]). Moreover, graded hypoxia (*P*~O~2~~ 100--40 mmHg) produced graded depression of contraction evoked by stimulation of α~1~-adrenoceptors in rat iliac and other arteries ([@b9]; [@b42]; [@b15]; [@b1]). However, sympathetically evoked vasoconstriction in skeletal muscle is partly mediated by α~2~-adrenoceptors ([@b41]; [@b7]) and α~2~-adrenoceptor-evoked arteriolar constriction is particularly vulnerable to local hypoxia ([@b56]). Whether the α~2~-adrenoceptor component of sympathetic vasoconstriction is blunted by systemic hypoxia has not been examined. Further, there is little pharmacological evidence on the contribution of NPY to sympathetically evoked vasoconstriction in skeletal muscle *in vivo* (see [@b20]).

Thus, we tested the hypotheses that severe systemic hypoxia blunts muscle vasoconstriction evoked by sympathetic chain stimulation with high and low frequency patterns chosen to mimic the range of MSNA that occur at rest and during reflex activation, by limiting the components that are mediated by α~2~-adrenoceptors and by NPY acting on Y~1~ receptors, the NPY receptors that are mainly responsible for inducing vasoconstriction ([@b38]).

Methods
=======

Experiments were performed on two groups of male Wistar rats. All experiments were approved by UK legislation under the Home Office Animals (Scientific Procedures) Act 1986. Anaesthesia was induced with halothane (3.5% in O~2~) and judged to be of a surgical level when pedal withdrawal reflexes were absent. A jugular vein was then cannulated for continuous infusion of the anaesthetic Saffan (Schering-Plough Animal Health, Welwyn Garden City, UK) at 7--12 mg kg^−1^ h^−1^. Thereafter, the level of anaesthesia was judged to be adequate by the absence of withdrawal reflexes and stability of arterial blood pressure (ABP), as we have previously described ([@b6]). At the end of the experiments all animals were killed by anaesthetic overdose.

The surgical preparation of the animal and the recording techniques were essentially as we have described before ([@b6]). Briefly, the trachea was cannulated and the side-arm of the cannula was connected to a system of rotameters in a gas proportioner frame (CP Instruments, Hanwell, London, UK), allowing the rats to breathe either a normoxic (21% O~2~ in N~2~) or a hypoxic (8% O~2~ in N~2~) gas mixture, as described below. Both brachial arteries were cannulated, one being used to monitor arterial blood pressure (ABP), the other allowing 150 μl samples to be taken anaerobically for analysis by a blood gas analyser (IL1640; Instrumentation Laboratories, Warrington, Cheshire, UK): samples were taken in normoxia and during hypoxia following the period of sympathetic stimulation (see below). The caudal ventral tail artery was retrogradely cannulated to allow administration of drugs predominantly to the right hindlimb from which blood flow was recorded (see below). The left femoral vein was cannulated to allow administration of pharmacological antagonists.

A bipolar, silver-wire stimulating electrode was attached to the right lumbar sympathetic chain between L3 and L4 via a laparotomy, the great vessels being temporarily retracted to expose the sympathetic chain. The electrode tips were embedded in dental impression material (President, Light Body, Colténe, Switzerland) to both mechanically fix and electrically isolate them. The electrodes were used to deliver three different patterns of nerve stimulation at constant current via an isolated stimulator (DS2A; Digitimer, UK). The patterns delivered the same number of 1 ms pulses at a constant current of 1 mA in a 1 min period (see [@b6]): (1) continuous stimulation at 2 Hz, (2) a 20 Hz burst for 1 s repeated every 10 s (bursts at 20 Hz), and (3) a 40 Hz burst for 0.5 s repeated every 10 s (bursts at 40 Hz). Each pattern resulted in 120 impulses being delivered over the 1 min stimulation period: they were delivered in random order.

Blood flow was recorded from the right femoral artery (FBF) via a perivascular flowprobe (0.7V; Transonic Systems, Ithaca, NY, USA) connected to a flowmeter (T106; Transonic Systems). ABP and FBF were acquired into Chart software (ADInstruments) via a MacLab/8 s (ADInstruments) at a sampling frequency of 100 Hz. Mean arterial pressure (MAP) and heart rate (HR) were derived on-line from the ABP signal, and femoral vascular resistance (FVR) was calculated on-line, by the division of ABP by FBF.

Protocols
---------

### Group 1: sympathetic stimulation before and after α~2~-adrenoceptor antagonism

The responses evoked by sympathetic stimulation with bursts at 40 and 20 Hz and by continuous stimulation at 2 Hz were tested in seven rats (body mass 218 ± 8 g: mean ±[s.d.]{.smallcaps}) during normoxia. The inspirate was then switched to hypoxia (8% O~2~) and at least 1 min after a new steady baseline had been achieved, the responses evoked by sympathetic stimulation were re-tested. The inspirate was then returned to normoxia and the animal allowed to recover for at least 10--15 min. The α~2~-adrenoceptor antagonist yohimbine (Sigma, UK) was administered intravenously at a dose of 0.5 mg kg^−1^ and following an equilibration period of 10--15 min, the responses to stimulation were re-tested under both normoxic and hypoxic conditions. In previous studies, this dose of yohimbine was shown to selectively and maximally inhibit α~2~-adrenoceptor-mediated sympathoinhibition ([@b54]). In pilot studies this dose abolished the increase in ABP evoked by infusion of the α~2~-adrenoceptor agonist UK14304 (A. M. Coney & J. M. Marshall, unpublished observations).

### Group 2: sympathetic stimulation before and during infusion of an NPY Y~1~ receptor antagonist

This protocol was performed in seven rats (mean ±[s.d.,]{.smallcaps} body mass 213 ± 11 g). The protocol was essentially the same as for Group 1, except that when the responses to all three patterns of sympathetic stimulation had been tested in normoxia and during hypoxia, the animal was allowed to recover in normoxia for at least 10--15 min and then the NPY Y~1~ receptor antagonist BIBP 3226 (Sigma, UK) was infused through the caudal ventral artery at a rate of 10 μg kg^−1^ min^−1^. Responses evoked in normoxia, and in acute hypoxia were then re-tested as described above. This regime for administration of BIBP 3226 was shown in a previous study on the rat to selectively reduce the facilitation produced by NPY of peripheral vasoconstrictor responses evoked by α~1~-adrenoceptor stimulation ([@b2]). Further, in a pilot study on four rats, we found that administration of Leu-Pro NPY (a Y~1~ agonist) at 128 μg kg^−1^ increased ABP by 32 ± 3 mmHg. This was completely abolished by the above regime of BIBP 3226 administration.

Data analysis
-------------

All data are expressed as mean ±[s.e.m.]{.smallcaps} Data were analysed as described in [@b6]. Thus, FVR (mmHg ml^−1^ min) was computed on-line by the division of ABP by FBF and the size of the constrictor response to sympathetic stimulation was calculated by subtracting the integral of baseline FVR calculated from the 1 min preceding the stimulus, from the integral of FVR measured during the 1 min stimulus. The integrated constrictor response was expressed in arbitrary resistance units (RU). This allowed comparison between responses evoked by different patterns of stimulation as well as between responses evoked from different baseline values of FVR, i.e. during normoxia and hypoxia. Differences in baseline and in integrated FVR before and after each antagonist were determined by repeated measures ANOVA followed by Student--Newman--Keuls *post hoc* test if *P* \< 0.05.

Results
=======

Group 1
-------

During normoxia, stimulation of the sympathetic chain with bursts at 40 Hz and 20 Hz and continuously at 2 Hz each evoked significant vasoconstriction in hindlimb muscle: integrated FVR increased by 3.25 ± 0.75, 3.71 ± 1.18 and 2.72 ± 0.83 RU, respectively. Continuous stimulation at 2 Hz tended to evoke smaller responses than bursts at 40 or 20 Hz, as previously reported, even though the same number of impulses was delivered in each case (see [Fig. 1](#fig01){ref-type="fig"} and [@b6]). These vasoconstrictor responses each resulted in a significant decrease in FBF (data not shown, see [@b6]).

![Effects of hypoxia and yohimbine on vasoconstrictor responses evoked in the hindlimb by different patterns of sympathetic stimulation\
Left panel shows baseline values of integrated femoral vascular resistance (FVR) over 1 min recorded immediately prior to sympathetic stimulation. Right panels indicate the responses evoked by the 3 patterns of sympathetic stimulation and show the mean ±[s.e.m.]{.smallcaps} of the change in integrated FVR (ΔInt FVR). Labels below columns indicate normoxia (N), hypoxia (H) and yohimbine (Yoh). Symbols indicate statistical significance of *P* \< 0.05 (one symbol) and *P* \< 0.01 (two symbols) where \*=*versus* normoxia before or after yohimbine; †=*versus* before yohimbine in normoxia or hypoxia; and ‡=*versus* hypoxia before yohimbine.](tjp0582-1349-f1){#fig01}

Switching the inspirate to 8% O~2~ induced the expected fall in arterial *P*~O~2~~ (*P*~aO~2~~) with a fall in arterial *P*~CO~2~~ (*P*~aCO~2~~) and alkalosis, reflecting the hypoxia-induced hyperventilation ([Table 1](#tbl1){ref-type="table"}). Concomitantly, there was a significant fall in FVR indicating vasodilatation in hindlimb muscle, with FBF maintained despite the fall in ABP ([Fig. 1](#fig01){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}), as we have described before (see [@b6] and references therein). During hypoxia, the increase in FVR evoked by each pattern of sympathetic stimulation was attenuated as we have described before ([@b6]), although the effect on the response evoked by bursts at 20 Hz just failed to reach statistical significance (*P* = 0.0514). The increase in FVR evoked by continuous stimulation at 2 Hz was reduced by a greater extent than those evoked by bursts at 20 and 40 Hz (by 96 *versus* 49% and 64%, respectively; see [@b6]; [@b5]).

###### 

Arterial blood gas and pH values in all groups in different conditions

                                   *P*~aO~2~~ (mmHg)    *P*~aCO~2~~ (mmHg)   pH
  --------- ---------------------- -------------------- -------------------- -----------------------
  Group 1   Normoxia               81.9 ± 3.2           38.4 ± 1.4           7.422 ± 0.013
            Hypoxia                27.9 ± 1.0^\*\*\*^   22.9 ± 1.3^\*\*\*^   7.542 ± 0.014^\*\*\*^
            Normoxia + yohimbine   93.3 ± 4.0           36.4 ± 2.2           7.428 ± 0.014
            Hypoxia + yohimbine    32.0 ± 1.8^\*\*\*^   23.7 ± 1.8^\*\*\*^   7.496 ± 0.035
  Group 2   Normoxia               86.3 ± 4.1           39.3 ± 1.8           7.367 ± 0.023
            Hypoxia                34 ± 1.3^\*\*\*^     27.6 ± 1.1^\*\*\*^   7.451 ± 0.015^\*\*\*^
            Normoxia + BIBP 3226   88.2 ± 3.1           38.2 ± 2.1           7.372 ± 0.031
            Hypoxia + BIBP 3226    33.7 ± 1.6^\*\*\*^   28.1 ± 1.3^\*\*\*^   7.446 ± 0.012^\*\*\*^

Values are mean ± [s.e.m.]{.smallcaps} Normoxia (air breathing) and hypoxia (breathing 8% O~2~) in the absence or presence of either yohimbine or BIBP 3226. Asterisks indicate statistical significance of *P* \< 0.001 (\*\*\*) compared to normoxia.

###### 

Baseline cardiovascular variables in all groups in different conditions

                                   ABP (mmHg)       HR (beats min^−1^)   FBF (ml min^−1^)   FVR (mmHg ml^−1^ min)
  --------- ---------------------- ---------------- -------------------- ------------------ -----------------------
  Group 1   Normoxia               106 ± 5          419 ± 19             1.26 ± 0.08        85.7 ± 6.1
            Hypoxia                58 ± 6^\*\*^     407 ± 35             1.11 ± 0.20        57.8 ± 6.7^\*^
            Normoxia + yohimbine   100 ± 4          442 ± 17             1.25 ± 0.30        103.6 ± 18.6
            Hypoxia + yohimbine    62 ± 6^\*\*^     429 ± 29             1.24 ± 0.32        63.0 ± 10.6^\*\*^
  Group 2   Normoxia               125 ± 5          451 ± 16             2.16 ± 0.37        69.6 ± 10.2
            Hypoxia                74 ± 4^\*\*\*^   488 ± 36             1.83 ± 0.18        42.4 ± 3.7^\*^
            Normoxia + BIBP 3226   123 ± 6          481 ± 18             2.11 ± 0.18        61.6 ± 5.8
            Hypoxia + BIBP 3226    77 ± 5^\*\*^     502 ± 24             2.22 ± 0.33        38.3 ± 4.2^\*\*^

Values are mean ± [s.e.m.]{.smallcaps} Normoxia (air breathing) and hypoxia (breathing 8% O~2~) in the absence or presence of either yohimbine or BIBP 3226. Asterisks indicate statistical significance of *P* \< 0.05 (\*), *P* \< 0.01 (\*\*) and *P* \< 0.001 (\*\*\*) compared to normoxia. ABP, arterial blood pressure; HR, heart rate; FBF, femoral blood flow; FVR, femoral vascular resistance.

Administration of the α~2~-antagonist yohimbine had no effect on any of the cardiovascular baselines or blood gas values recorded in normoxia ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Notably, baseline FVR did not change, suggesting no net role for α~2~-adrenoceptors in the maintenance of vascular tone in hindlimb (see Discussion). However, yohimbine significantly attenuated the vasoconstrictor responses evoked in normoxia by sympathetic stimulation with bursts at 20 Hz and 40 Hz, but not that evoked by continuous stimulation at 2 Hz.

When the inspirate was switched to 8% O~2~, the blood gas values were similar to those recorded in hypoxia before yohimbine ([Table 1](#tbl1){ref-type="table"}). Further, baseline ABP and FVR fell significantly to similar levels to those recorded in hypoxia before yohimbine ([Table 2](#tbl2){ref-type="table"}, [Fig. 1](#fig01){ref-type="fig"}). Under these conditions, the increases in FVR evoked by sympathetic stimulation with all three patterns were attenuated compared to those evoked in normoxia after yohimbine ([Fig. 1](#fig01){ref-type="fig"}). This did not reach statistical significance for the response to 20 Hz (*P* = 0.1) probably reflecting the variability of the responses evoked by bursts at 20 Hz in normoxia (see [Fig. 1](#fig01){ref-type="fig"}). Nevertheless the results indicated that yohimbine did not prevent an attenuating effect of hypoxia on the sympathetically evoked vasoconstrictor responses. There were no significant differences between the increase in FVR evoked by sympathetic stimulation in hypoxia after yohimbine compared to those evoked in hypoxia before yohimbine, i.e. hypoxia reduced the constrictor responses to the same levels before and after yohimbine ([Fig. 1](#fig01){ref-type="fig"}). On the other hand, the increases in FVR evoked by bursts at 40 Hz and continuous stimulation at 2 Hz in normoxia after yohimbine were significantly greater than those evoked during hypoxia before yohimbine ([Fig. 1](#fig01){ref-type="fig"}). In other words, hypoxia attenuated these vasoconstrictor responses to a greater extent than yohimbine.

Group 2
-------

The blood gas values and baseline cardiovascular variables recorded during normoxia were similar to those of Group 1 ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). In normoxia, stimulation of the sympathetic chain with all three patterns of stimulation evoked increases in FVR that were similar to those evoked in Group 1. Moreover these responses were attenuated during hypoxia as in Group 1 ([Fig. 3](#fig03){ref-type="fig"} cf. [Fig. 1](#fig01){ref-type="fig"}). Typical responses evoked by bursts at 40 Hz under the different experimental conditions are shown in [Fig. 2](#fig02){ref-type="fig"}.

![Original recordings of responses evoked by the 40 Hz bursting pattern of sympathetic nerve stimulation during air breathing and systemic hypoxia in the absence and presence of the NPY antagonist BIBP 3226\
The periods of stimulation are indicated by bars under each response whilst the infusion of BIBP 3226 is indicated by the bar under the right panels. ABP, arterial blood pressure; FBF, femoral blood flow; FVR, femoral vascular resistance.](tjp0582-1349-f2){#fig02}

![Effects of hypoxia and BIBP 3226 on vasoconstrictor responses evoked in the hindlimb by different patterns of sympathetic stimulation\
Left panel shows baseline values of integrated FVR over 1 min recorded immediately prior to sympathetic stimulation. Right panels indicate the responses evoked by the 3 patterns of sympathetic stimulation and show the mean ±[s.e.m.]{.smallcaps} of the change in integrated FVR (ΔInt FVR). Labels below the columns indicate normoxia (N), hypoxia (H) and BIBP 3226 (BIBP). Symbols indicate statistical significance of *P* \< 0.05 (one symbol) and *P* \< 0.01 (two symbols) where \*=*versus* normoxia; †=*versus* before BIBP 3226 in normoxia or hypoxia.](tjp0582-1349-f3){#fig03}

Infusion of the Y~1~ antagonist BIBP 3226 had no effect on the blood gas values or cardiovascular baselines (see [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, [Fig. 3](#fig03){ref-type="fig"}). The constrictor responses evoked by the different patterns of sympathetic stimulation in normoxia were differentially affected by BIBP 3226. Thus, the increase in FVR evoked by bursts at 40 Hz was attenuated, while the increase in FVR evoked by bursts at 20 Hz and by continuous stimulation at 2 Hz was not different from that evoked before BIBP 3226 ([Fig. 3](#fig03){ref-type="fig"}).

Infusion of BIBP 3226 had no effect on the hypoxia-induced changes in blood gases, nor on the fall in baseline ABP and FVR ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, [Fig. 3](#fig03){ref-type="fig"}). Further, in the presence of BIBP 3226, hypoxia still reduced the increase in FVR evoked by each pattern of sympathetic stimulation ([Fig. 3](#fig03){ref-type="fig"}). However, the increase in FVR evoked by bursts at 40 Hz reached a lower level in hypoxia during BIBP 3226 infusion than it did in hypoxia before BIBP 3226 ([Fig. 3](#fig03){ref-type="fig"}). There was a trend for a similar effect of BIBP 3226 on the increase in FVR evoked in hypoxia by bursts at 20 Hz although this failed to reach statistical significance (*P* = 0.101). On the other hand the increase in FVR evoked by continuous stimulation at 2 Hz in hypoxia during BIBP 3226 infusion was similar to that evoked in hypoxia before the antagonist ([Fig. 3](#fig03){ref-type="fig"}).

Discussion
==========

The present study confirmed that severe systemic hypoxia attenuates the increase in FVR evoked in the hindlimb by each of three different patterns of sympathetic stimulation: continuous stimulation at 2 Hz and bursts at 20 and 40 Hz (see [@b6]; [@b5]). The new findings were (i) that the α~2~-adrenoceptor antagonist yohimbine had no effect on baseline FVR, but (ii) reduced the increases in FVR evoked by high frequency bursts of sympathetic stimulation in normoxia, whilst (iii) having no effect on the attenuation of the responses evoked by any of the three patterns of stimulation in hypoxia. On the other hand (iv) the Y~1~ receptor antagonist BIBP 3226 had no effect on baseline FVR, but (v) reduced the increase in FVR evoked in normoxia by high frequency bursts, and (vi) in hypoxia, these responses were reduced to a greater extent than they were in the absence of this antagonist.

Role of α~2~-adrenoceptors in hindlimb
--------------------------------------

A substantial component of the vasoconstrictor tone in rat hindlimb under conditions comparable to the normoxic condition of the present study is dependent on α-adrenoceptor stimulation ([@b23]), in common with other studies on limb muscle (e.g. [@b27]; [@b22]; [@b55]; [@b7]). Our new finding that the α~2~-adrenoceptor antagonist yohimbine had no effect on baseline FVR under normoxic conditions indicates that α~2~-adrenoceptor stimulation makes no overall contribution to resting tone in rat limb muscle in Saffan-anaesthetized rats. This may be because the noradrenaline that is tonically released from the sympathetic varicosities exerts a minimal vasoconstrictor effect by stimulating postjunctional α~2~-adrenoceptors. However, it may also be that the inhibitory effect of yohimbine on postjunctional α~2~-adrenoceptors is offset by its inhibitory effect on prejunctional α~2~-adrenoceptors whose stimulation inhibits noradrenaline release ([@b51]). Another possibility concerns the location of the postjunctional receptors. Studies on the cremaster muscle of the rat, showed that the distal arterioles have α~2~- but not α~1~-adrenoceptors and constrictor responses evoked by sympathetic nerve stimulation were mediated entirely by α~2~-adrenoceptors; proximal arterioles have α~1~- and α~2~-adrenoceptors, but their responses to sympathetic stimulation were mediated by α~1~-adrenoceptors ([@b14]; [@b41]). Thus, if innervated α~2~-adrenoceptors are predominantly located on the distal arterioles of hindlimb muscle, it could be that tonically released noradrenaline constricts these arterioles, but removal of this influence has little effect on gross vascular resistance i.e. FVR.

In human forearm, an α~2~-adrenoceptor antagonist, whether given alone, or after an α~1~-adrenoceptor antagonist, suggested that α~2~-adrenoceptor stimulation is responsible for 50--60% of resting vascular tone ([@b7]). This apparent disparity between rat and human may reflect differences in the relative importance of pre- and postjunctional α~2~-adrenoceptors and/or in the contribution of the resistance of distal arterioles to *gross* vascular resistance. Alternatively, the patterning of MSNA may be different in resting human subjects and rats under Saffan anaesthesia and may influence the relative importance of α~2~-adrenoceptors.

That yohimbine reduced the increase in FVR evoked by sympathetic stimulation with high frequency bursts by ∼25--30% is consistent with this possibility. Assuming the innervated α~2~-adrenoceptors are located on the distal arterioles, our findings indicate that during high frequency bursts, noradrenaline causes substantial constriction of distal arterioles by stimulating α~2~-adrenoceptors and this exerts a substantial influence on FVR. Thus, it may be that the MSNA in the resting human subjects studied by [@b7] was of a higher average frequency, or contained more high frequency bursts than in the Saffan-anaesthetized rat.

In a previous study on pithed rats with consequent low ABP, in which hindlimb muscle was perfused at constant flow, the increases in FVR evoked by sympathetic stimulation at frequencies of 2--4 Hz were *potentiated* by α~2~-adrenoceptor blockade, whereas those evoked by stimulation at higher frequencies up to 100 Hz were not affected ([@b35]). These results suggested a preferential influence of presynaptic α~2~-adrenoceptor stimulation at low frequencies, but revealed no constrictor role for postsynaptic α~2~-adrenoceptors at any frequency. It seems reasonable to suggest that the results of the present study on anaesthetized rats with an intact central nervous system supersede these earlier findings. Our finding that the depressive effect of yohimbine on the increase in FVR evoked by continuous stimulation at 2 Hz failed to reach statistical significance, may reflect the opposing influences of pre- and postsynaptic α~2~-adrenoceptor stimulation on this response. However, our findings on the effect of yohimbine on increases in FVR evoked by bursts add to the evidence that stimulation of postjunctional α~2~-adrenoceptors contributes to sympathetically evoked increases in muscle vascular resistance in humans ([@b3]; [@b21]; [@b55]), cats and dogs ([@b16]; [@b13]).

Turning to systemic hypoxia, yohimbine had no effect on the hypoxia-induced fall in FVR. Moreover, in the presence of α~2~-adrenoceptor blockade, hypoxia still reduced the increases in FVR evoked by all three patterns of sympathetic stimulation relative to those evoked in normoxia, such that the remaining responses were comparable to those evoked in hypoxia in the absence of α~2~-adrenoceptor blockade (to ∼65, 50 and 15% of the control response for bursts at 40 and 20 Hz and continuous stimulation at 2 Hz, respectively). This finding clearly indicates that systemic hypoxia blunts a component of sympathetic vasoconstriction in muscle that is *not* mediated by α~2~-adrenoceptors. This may include the component mediated by α~1~-adrenoceptors, given this was blunted in rat iliac artery when *P*~O~2~~ was reduced below 70 mmHg ([@b1]). However, our new finding also suggests that a substantial part of the blunting effect of systemic hypoxia on sympathetically evoked vasoconstriction is attributable to blunting of the α~2~-adrenoceptor-induced component in distal arterioles. If this were not the case, the vasodilatation induced by hypoxia *per se* would have been expected to be *potentiated* after yohimbine, for systemic hypoxia increases the average frequency of MSNA beyond 2 Hz and contains bursts of up to 50 Hz ([@b19]). Moreover, the increases in FVR evoked by sympathetic stimulation in hypoxia would have been expected to be *smaller* than those evoked in hypoxia in the absence of α~2~-adrenoceptor blockade. In fact, the data suggest that blunting of the α~2~-adrenoceptor component explains ∼50% of the full effect of systemic hypoxia on the responses evoked by high frequency bursts and ∼30% of that evoked by continuous stimulation at 2 Hz (see [Fig. 1](#fig01){ref-type="fig"}). Clearly, this proposal contrasts with the conclusion of [@b8] that systemic hypoxia does not blunt either the α~1~- or α~2~-adrenoceptor component of sympathetic vasoconstriction in human forearm. This disparity may be explained by the fact that the level of systemic hypoxia achieved in the present study was more severe (*P*~aO~2~~ 35 *versus* 28 mmHg), or by the fact that [@b8] stimulated the sympathetic fibres pharmacologically with tyramine which selectively releases noradrenaline from the varicosities: the effect of noradrenaline on its postsynaptic receptors may be very different to when electrical or reflex activation of the sympathetic fibres releases all three cotransmitters.

There is substantial evidence that the α~2~-adrenoceptor component of vasoconstriction is vulnerable to local factors. Thus, α~2~-mediated vasoconstriction of terminal arterioles in skeletal muscle *in vivo* was reported to be very sensitive to inhibition by acidosis and to reduced O~2~ delivery ([@b31]; [@b40]), while α~2~-mediated constriction of muscle arterioles *in vitro* was attenuated by severe hypoxia (*P*~O~2~~: 10 mmHg, [@b56]). Further, the increase in vascular resistance evoked by infusion of an α~2~-adrenoceptor agonist in rat hindlimb was inhibited during muscle contraction ([@b58]). Ours is the first study to indicate that α~2~-mediated vasoconstriction evoked by sympathetic nerve activity is blunted by systemic hypoxia.

The blunting of the α~2~-mediated constriction by hypoxia in muscle arterioles *in vitro*, and that caused by muscle contraction *in vivo*, has been attributed to the opening of ATP-sensitive K^+^ (K~ATP~) channels on vascular smooth muscle ([@b56]; [@b59]): K~ATP~ channel opening may impair α~2~-mediated influx of Ca^2+^ through voltage-sensitive Ca^2+^ channels ([@b51]). We previously provided evidence that the opening of K~ATP~ channels, probably caused by locally released adenosine, contributes to the muscle vasodilatation of systemic hypoxia ([@b34]). Thus, it is reasonable to propose that the opening of K~ATP~ channels underlies the blunting of the α~2~ component of sympathetic vasoconstriction in systemic hypoxia.

Role of NPY
-----------

That the selective NPY Y~1~ receptor antagonist BIBP 3226 had no effect on baseline FVR or ABP in normoxia indicates that NPY acting on Y~1~ receptors plays no significant role in maintaining resting vascular tone in hindlimb, or ABP in Saffan-anaesthetized rats. This is consistent with evidence that NPY does not contribute to maintenance of resting ABP in normotensive rats, or humans ([@b37]; [@b62]).

In contrast with these findings, [@b20] reported that BIBP 3226 caused an increase in baseline vascular conductance of hindlimb of anaesthetized rats that was equivalent to that induced by α~1~-adrenoceptor blockade, implying a major role for NPY in determining basal vascular tone. The discrepancy with the present results might be attributed to the fact that [@b20] used Sprague--Dawley rats whereas we used Wistars. However, it seems more likely that the explanation lies in the status of the cardiovascular system and this may, in turn, reflect the anaesthetic regime: [@b20] used barbiturate whereas we used the steroid anaesthetic Saffan (alphaxalone--alphadalone). The rats used by [@b20] were larger than those of the present study (256--426 g *versus* 218 and 213 g in Groups 1 and 2, respectively) and baseline levels of ABP were similar (103--106 *versus* 106 and 125 mmHg, respectively), and yet baseline FBF was considerably lower in the study of [@b20]: ∼0.028--0.018 *versus* 1.26 and 2.16 ml min^−1^ in Groups 1 and 2, respectively. Certainly, recent evidence indicates that barbiturate anaesthesia induces a sympathetically mediated increase in hindlimb vascular resistance ([@b57]). This would be consistent with a higher average frequency of MSNA and/or more high frequency bursts under the baseline conditions of [@b20]. If this were the case, their results would be consistent with the evidence that NPY becomes important as a vasoconstrictor in skeletal muscle and other vasculature when the frequency of sympathetic nerve activity is high ([@b45]; [@b39]; [@b28]).

In further accord with this concept, BIBP 3226 reduced the increase in FVR evoked in normoxia by bursts at 40 Hz by ∼20%, tended to reduce that evoked by bursts at 20 Hz, but had no effect on the increase in FVR evoked by continuous stimulation at 2 Hz. This finding clearly agrees with evidence that exogenous NPY can produce vasoconstriction in cat and human skeletal muscle vasculature by stimulating Y~1~ receptors ([@b43]; [@b44]) and that NPY released by sympathetic stimulation evokes constriction in pig skeletal muscle by stimulating Y~1~ receptors ([@b29]). Studies on cat hindlimb muscle, involving intravascular pressure measurements at different levels of the vascular tree and on rat cremaster muscle by intravital microscopy, indicated that infused or topically applied NPY, respectively, evoked constriction of proximal *and* distal arterioles ([@b25]; [@b12]). There has been no comparable study of the site(s) of action of NPY released from the sympathetic varicosities. Thus, the contribution of NPY we have identified in sympathetically evoked increases in FVR in normoxia may have reflected constrictor influences on proximal and/or distal arterioles.

Since in the presence of Y~1~ receptor blockade, systemic hypoxia still caused a further reduction in the increase in FVR evoked by high frequency bursts and continuous low frequency stimulation, this confirms that hypoxia blunts the *non*-NPY-mediated component of the vasoconstriction. However, the fact that in hypoxia, the increase in FVR evoked by bursts at 40 Hz was smaller in the presence of BIBP 3226 than in its absence, allows the novel proposal that the NPY-mediated component of this response is resistant even to the severe level of systemic hypoxia used in the present study. Since we have argued above that the constriction of distal arterioles that is evoked by high frequency bursts is mediated by α~2~-adrenoceptors and is blunted by systemic hypoxia, it seems likely that it was the NPY-induced constriction of the proximal arterioles that was resistant to the effects of hypoxia. However, it has to be acknowledged that our results may not fully describe the actions of NPY since it is possible that it may also act prejunctionally on Y~2~ receptors to inhibit neurotransmitter release.

Interactions between cotransmitters and functional implications
---------------------------------------------------------------

It is well established that the sympathetic cotransmitters facilitate the actions of one another ([@b48]; [@b39]). In accord with this, we recently showed that blockade of α~1~- and α~2~-adrenoceptors with phentolamine virtually abolished the increases in FVR evoked by a range of different patterns of sympathetic stimulation, while desensitization of the P2×1 purinergic receptors with αβ-methylene-ATP reduced these responses by as much as 40--60% ([@b23]). Further, there is *in vitro* evidence that NPY given exogenously or released by sympathetic nerve stimulation facilitates the constrictor influence of both noradrenaline and ATP ([@b39]; [@b47]). Thus, the inhibitory effects of yohimbine and BIBP 3226 on the increase in FVR evoked by high frequency bursts in normoxia cannot be taken to simply indicate the *direct* contributions of α~2~-adrenoceptor and Y~1~ receptor stimulation to these responses: either receptor antagonist may remove *both* the direct constrictor action of that receptor and the facilitatory influence of its stimulation on the response evoked by another transmitter. It is possible that yohimbine not only inhibited the α~2~-adrenoceptor component of distal arteriolar constriction, but also any constriction induced in these and proximal arterioles by nerve-released noradrenaline and/or ATP acting on α~1~-adrenoceptors and P2X receptors, respectively. Further, BIBP 3226 is likely to have inhibited the facilitatory influence of NPY on constriction evoked in proximal and distal arterioles by nerve-released noradrenaline acting on α~1~- and α~2~-adrenoceptors and by ATP acting on P2X receptors.

The fact that the effects of these two antagonists were differentially affected by severe systemic hypoxia allows important functional proposals. Thus, it seems likely that α~2~-adrenoceptor constriction of distal arterioles induced directly, or indirectly, by the high frequency bursts of sympathetic activity induced by systemic hypoxia *per se* and by additional inputs to the central nervous system, is blunted during severe systemic hypoxia. This would help to maximize the dilatation of distal arterioles caused by locally released adenosine and NO and accords with direct and indirect evidence that dilatation of distal arterioles of skeletal muscle during systemic hypoxia facilitates the distribution of the available O~2~ to the capillary network and allows muscle O~2~ consumption to be maintained ([@b36]; [@b10],[@b11]). On the other hand, if the direct and indirect influence of the NPY released by high frequency bursts of sympathetic activity on the proximal arterioles of muscle is preserved during severe systemic hypoxia, this would allow some sympathetic control over the vascular resistance of skeletal muscle to be retained. Indeed, in severe systemic hypoxia, as in sepsis, haemorrhage and cold stress ([@b63]; [@b46]), sympathetically released NPY may provide a crucial means of regulating muscle vascular resistance and therefore ABP.
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